IASLC World Conference on Lung Cancer

Published: 20-Sep-2016

The IASLC WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, doctors and specialists from more than 100 countries.

The conference goal is to increase awareness and collaboration so that the latest developments can be understood and implemented throughout the world.

The four-day conference will cover a range of disciplines including invited talks, formal research studies, and clinical trial results. All sessions will reveal new discoveries in the fight against lung cancer.

wclc2016.iaslc.org/

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  4. Interphex 16-18 April 2024 | Conference and Exhibition | New York, US
  5. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US

You may also like

Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Research & Development

Amarna Therapeutics appoints Aurelia Caparrós as new Chief Business Officer

Aurellia will be reponsible for driving Amarna's growth in the Netherlands and Spain
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Manufacturing

Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer

Denis will be responsible for optimising global operations for the company
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Subscribe now